CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 20:00:02 13/03/2026 GMT			5-day change	1st Jan Change
155.46 ^USD	+1.83%		-10.89%	-22.07%

03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-10	Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10:00 AM

Analyst Reco.

03-09	Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193	MT
02-25	UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating	MT
02-20	Rothschild & Co Redburn Adjusts Charles River Laboratories PT to $200 From $211, Maintains Buy Rating	MT
02-20	Mizuho Securities Adjusts Charles River Laboratories Price Target to $175 From $215, Maintains Neutral Rating	MT
02-20	TD Cowen Adjusts Price Target on Charles River Laboratories International to $235 From $251, Maintains Buy Rating	MT
02-19	Jefferies Adjusts Price Target on Charles River Laboratories International to $225 From $255, Maintains Buy Rating	MT
02-19	Barclays Adjusts Price Target on Charles River Laboratories International to $200 From $215, Maintains Overweight Rating	MT
02-19	Baird Adjusts Price Target on Charles River Laboratories International to $193 From $231, Maintains Outperform Rating	MT
02-18	JPMorgan Cuts Charles River Laboratories International Price Target to $165 From $190, Maintains Neutral Rating	MT
01-22	TD Cowen Adjusts Price Target on Charles River Laboratories International to $251 From $197, Maintains Buy Rating	MT
01-20	Jefferies Adjusts Price Target on Charles River Laboratories International to $255 From $205, Maintains Buy Rating	MT
01-20	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
01-16	Citigroup Adjusts Price Target on Charles River Laboratories International to $265 From $200, Maintains Buy Rating	MT
01-13	Baird Adjusts PT on Charles River Laboratories International to $231 From $224, Keeps Outperform Rating	MT
01-13	Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating	MT
01-09	Mizuho Adjusts Price Target on Charles River Laboratories International to $215 From $200, Maintains Neutral Rating	MT
12-19	Deutsche Bank Adjusts Price Target on Charles River to $230 From $205, Maintains Buy Rating	MT
12-18	Mizuho Adjusts Price Target on Charles River Laboratories International to $200 From $174, Maintains Neutral Rating	MT
12-15	Barclays Adjusts PT on Charles River Laboratories International to $215 From $210, Keeps Overweight Rating	MT
12-15	JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating	MT
12-15	BofA Securities Upgrades Charles River Laboratories International to Buy	MT
12-02	Jefferies Adjusts PT on Charles River Laboratories International to $205 From $200, Maintains Buy Rating	MT
11-17	Argus Upgrades Charles River Laboratories International to Buy From Hold, Price Target is $200	MT
11-11	Morgan Stanley Adjusts Charles River Laboratories International PT to $185 From $170, Maintains Equal Weight Rating	MT
11-10	TD Cowen Adjusts Price Target on Charles River Laboratories International to $197 From $205	MT